Mechanisms of Pathogenesis in Celiac Disease and Non-Celiac Gluten Sensitivity

Hugh J. Cornell¹ and Teodor Stelmasiak^2,

¹Former Adjunct Professor, School of Applied Science, RMIT University, Melbourne, Australia

²Former Director, Glutagen Pty Ltd, South Melbourne, Australia

Cite this paper:
Hugh J. Cornell and Teodor Stelmasiak. Mechanisms of Pathogenesis in Celiac Disease and Non-Celiac Gluten Sensitivity. International Journal of Celiac Disease. 2025; 13(1):4-9. doi: 10.12691/ijcd-13-1-2

Abstract

Celiac disease (CD) has in recent years become understood as a disease in which the importance of complete digestion of gliadin is essential for safe management of patients. Lately, the use of enzyme therapy for treatment of CD has gained wider acceptance as an adjunct to the gluten-free diet. A closer examination of Non-Celiac Gluten Sensitivity (NCGS) is warranted to determine if enzyme supplementation could be beneficial for individuals with this condition. Incomplete digestion of gluten produces toxic and/or immunologically active peptides which are implicated in both CD and in NCGS. These peptides are from a region close to the N-terminus of A-gliadin and contain serine or tyrosine residues. NCGS is caused by certain serine-containing peptides in A-gliadin and particularly those near the N-terminus. Peptide 11-19 is the most active of these peptides in vitro but may not be involved in cell-mediated immune reactions in CD. These reactions are related to tyrosine-containing peptides. Further along the chain is peptide 75-86, the most tissue damaging of the A-gliadin peptides in CD patients. This peptide is a tyrosine-containing peptide where damage caused to mucosal tissue is greater in CD than in NCGS. Hence, although CD and NCGS are both caused by gluten, the pathogenesis of the diseases has different mechanisms. However, both serine-containing and tyrosine-containing peptides are attacked by caricain, the protective enzyme in GluteGuard, thus rendering both types of toxic peptides harmless to the intestinal mucosa of susceptible individuals. Just as has been seen with Dermatitis Herpetiformis (DH), gluten is becoming a focus for several conditions when the neurological effects of gluten need to be considered.

Keywords:
celiac disease enzyme therapy non-celiac gluten sensitivity caricain dermatitis herpetiformis

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, Ilonen J, Laurila K, Dahlbom I, Hansson T, Höpfl P, Knip M. Prevalence of Celiac disease among children in Finland. N Engl J Med. 2003; 348(25): 2517-24.
[2]	Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiological approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology. 1992; 102(1): 330-54.
[3]	Anderson CM. Recent trends in the diagnosis and treatment of coeliac disease. Med J Aust. 1953; 2(6): 211-3.
[4]	Duggan JM. Recent developments in our understanding of adult coeliac disease. Med J Aust.1997; 166(6): 312-5. Dicke WK, Weijers HA, van der Kamer. Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr (Stockh). 1953; 42(1): 34-42.
[5]	Cornell HJ, Rivett DE. In vitro mucosal digestion of synthetic gliadin-derived peptides in celiac disease. J Protein Chem. 1995 Jul; 14(5): 335-9.
[6]	Cornell HJ. Partial in vitro digestion of active gliadin-related peptides in celiac disease. J Protein Chem. 1998; 17(8): 739-44.
[7]	Cornell HJ, Townley RRW. Investigating possible intestinal peptidase deficiency in coeliac disease. Clin Chim Acta. 1973; 43:113–125.
[8]	Cornell HJ, Stelmasiak T. The significance of key amino acid sequences in the digestibility and toxicity of gliadin peptides in celiac disease. Int. J. of Celiac Disease. 2016 4: 113-120.
[9]	Frazer AC, Fletcher RF, Ross CA, Shaw B, Sammons HG, Schneider R. Gluten-induced enteropathy: the effect of partially digested gluten. Lancet. 1959; 2(7097): 252-5
[10]	Falchuk ZM, Gebhard RL, Sessoms C, Strober W. An in vitro model of gluten-sensitive enteropathy. Effect of gliadin on intestinal epithelial cells of patients with gluten-sensitive enteropathy in organ culture. J Clin Invest. 1974; 53(2): 487-500.
[11]	Mäki M, Collin P. Coeliac disease. Lancet. 1997; 349: 1755-9.
[12]	Sturgess R, Day P, Ellis HJ, et al. Wheat peptide challenge in coeliac disease. Lancet. 1994; 343: 758–761.
[13]	Cornell HJ, Wieser H, Belitz HD. Characterisation of the gliadin-derived peptides which are biologically active in coeliac disease. Clin.Chim.Acta. 1992; 213: 37-50.
[14]	Cornell HJ, Stelmasiak T. A unified hypothesis of coeliac disease with implications for management of patients. Amino Acids. 2007; 33: 43–49.
[15]	Cornell HJ, Stelmasiak T, Lerner A. Enzyme therapy for patients with Celiac Disease – An Update. Int. Journal of Celiac Disease. 2013; 9: 28-34.
[16]	Bjarnason I, Peters TJ, Veall N. Intestinal permeability defect in coeliac disease. Lancet. 1983; 1(8336): 1284-5.
[17]	Drago S, El Asmar R, Di Pierro M, Grazia Clemente M, Tripathi A, Sapone A, Thakar M, Iacono G, Carroccio A, D'Agate C, Not T, Zampini L, Catassi C, Fasano A. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. 2006; 41(4): 408-19.
[18]	Schuppan D, Hahn EG. Gluten and the gut-lesions for immune regulation. Science. 2002; 297(5590): 2218-2220.
[19]	Mothes T, Mühle W, Müller F, Hekkens WT. Influence of gliadin on fetal chick intestine in tissue culture. Biol Neonate. 1985; 48(1): 59-64.
[20]	Cornell HJ, Skerritt JH, Puy R, Javadpour M. Studies of in vitro gamma-interferon production in coeliac disease as a response to gliadin peptides. Biochim Biophys Acta. 1994, 1226(2): 126-30.
[21]	McLachlan A, Cullis PG, Cornell HJ. The use of extended amino acid motifs for focussing on toxic peptides in coeliac disease. J Biochem Mol Biol Biophys. 2002; 6(5): 319-24.
[22]	De Ritis G, Auricchio S, Jones HW, Lew EJ, Bernardin JE, Kasarda DD. In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease. Gastroenterology. 1988 Jan; 94(1): 41-9.
[23]	Riecken EO, Stewart JS, Booth CC, Pearse AG. A histochemical study on the role of lysosomal enzymes in idiopathic steatorrhoea before and during a gluten-free diet. Gut. 1966; 7(4): 317-32.
[24]	Dolly J.O and Fottrell P.F. Effect of different peptide fractions from wheat gliadin on rat liver lysosomes.1969, Irish J. Med. Sci. 1969; 2,47.
[25]	Cooper BT, Holmes GT, Ferguson R, Thompson RA, Alan RN, Cooke WT. Gluten sensitive diarrhoea without evidence of celiac disease. Gastroenterology. 1981; 81, 192-194.
[26]	Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, Castillejo G, Ciacci C, Cristofori F, Dolinsek J, Francavilla R, Elli L, Green P, Holtmeier W, Koehler P, Koletzko S, Meinhold C, Sanders D, Schumann M, Schuppan D, Ullrich R, Vécsei A, Volta U, Zevallos V, Sapone A, Fasano A. Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients. 2013; 5(10): 3839-53.
[27]	Volta U, Tovoli F, Cicola R, Parisi C, Fabbri A, Piscaglia M, Fiorini E, Caio G. Serological tests in gluten sensitivity (nonceliac gluten intolerance). J Clin. Gastroenterology. 2012; 46(8): 680-685.
[28]	Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PH, Hadjivassiliou M, Kaukinen K, Rostami K, Sanders DS, Schumann M, Ullrich R, Villalta D, Volta U, Catassi C, Fasano A. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012; 10: 13.
[29]	Dieterich W, Ethnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D. Identification of tissue ransglutaminase as the autoantigen of celiac disease. Nat. Med.1997; 3: 797-801. Cartee AK, Choung RS, King KS, Wang S, Dzuris JL, Anderson RP, Van Dyke CT, Hinson CA, Marietta E, Katzka DA, Nehra V, Grover M, Murry JA. Plasma IL-2 and symptoms response after acute gluten exposure in subjects with Celiac Disease and Nonceliac Gluten Sensitivity. Am. J. Gastroenterology. 2022; 117: 319-326.
[30]	Cornell HJ, Wills-Johnson G. Structure activity relationships in coeliac-toxic gliadin peptides. Amino Acids 2001; 21: 243-253.
[31]	Zebrowska A, Cornell HJ, Macrae FA, Sysa-Jedrzejowska A, Waszczykowska A, Stelmasiak T. The effect of enzyme therapy on skin symptoms and immune responses in patients with dermatitis herpetiformis. Int.J.Celiac Dis. 2014; 2: 58-63.
[32]	Cornell HJ, Rolles CJ. Further evidence of a primary mucosal defect in coeliac disease. Gut. 1978; 19: 253 -9.
[33]	Jabri B, Sollid LM. T cells in Celiac Disease. J. Immunol. 2017; 198: 3005-3014.
[34]	Buddrick O, Cornell HJ, Small DM. Reduction of toxic gliadin content of wholegrain bread by the enzyme caricain. Food Chemistry. 2015; 170: 343-347.
[35]	Lerner A. Is enzyme supplementation effective strategy to reduce the burden of Gluten Free Diet in Celiac Disease? Int. J. Celiac Dis. 2016; 4: 38-39.
[36]	Buddrick O, Cornell HJ, Small DM. Reduction of toxic gliadin content of wholegrain bread by the enzyme caricain. Food Chemistry. 2015; 170: 343-347.
[37]	Lerner A. Is enzyme supplementation an effective strategy to reduce the burden of Gluten Free Diet in Celiac Disease? Int. J. Celiac Dis. 2016; 4: 38-39.